复星医药(600196.SH)：控股子公司药品芦沃美替尼片获临床试验批准

Core Viewpoint - Fosun Pharma has received approval from the National Medical Products Administration to conduct clinical trials for its drug, Rumaine (generic name: Luwomeitini tablets), in combination with Anlotinib for patients with advanced non-small cell lung cancer (NSCLC) with KRAS mutations [1] Group 1 - The clinical trial will focus on a new indication for Rumaine in treating advanced NSCLC [1] - The drug is an innovative small molecule chemical drug developed by the company, specifically a selective inhibitor of MEK1/2 [1] - The Phase II clinical trial is planned to be conducted within China once conditions are met [1]